The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation

Sold by Gardners

This product may not be approved for your region.
Hardback
  • Free Shipping

    On orders of AED 100 or more. Standard delivery within 8-10 days.
  • Free Reserve & Collect

    Reserve & Collect from Magrudy's or partner stores accross the UAE.
  • Cash On Delivery

    Pay when your order arrives.
  • Free returns

    See more about our return policy.
Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How do drug companies set prices and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? And how can an industry that produces life saving drugs have a poorer public reputation than gun and tobacco industries that produce products that kill? Ed Schoonveld, a leading expert and consultant in global pharmaceutical pricing and market access issues, explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers and the broader public to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.